Fairvalue-Calculator Fairvalue-Calculator
EN DE

Guangdong VTR Bio-Tech Co (300381) Fair Value & Analysis

Healthcare · CN · Market cap 2.8B CNY

Price¥5.97
Fair Value¥1.96
Upside-67.2%
Quality93/100
Evidence: Medium Range ¥1.01 – ¥3.45

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Guangdong VTR Bio-Tech Co (300381) currently trades at ¥5.97, while our model-based Fair Value estimate is ¥1.96 — implying the stock looks roughly 67.2% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Guangdong VTR Bio-Tech Co., Ltd. researches, develops, produces, sells, and services bio-enzyme preparations, biosynthetics, and nutrition and health products in China and internationally. The company offers animal nutrition and health, biofuel, detergent, food and beverage, brewing, starch sweetness, bakery, plant extracts, pulp and paper, and textile enzymes, as well as biotechnology solutions. It also provides active natural products. The company also exports its products. The company was founded in 1991 and is based in Zhuhai, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Guangdong VTR Bio-Tech Co (300381) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥1.96 versus a price of ¥5.97 — about −67% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 300381?
Our 21-model fair value for Guangdong VTR Bio-Tech Co is ¥1.96 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥5.97.
What is the quality score of 300381?
Guangdong VTR Bio-Tech Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.